Braeburn Pharmaceuticals’ Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services

By a News Reporter-Staff News Editor at Managed Care Weekly Digest -- - Braeburn Pharmaceuticals, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System (HCPCS) code, or permanent J-code, for Probuphine, the first and only six-month buprenorphine implant for the maintenance treatment of opioid addiction. The new J-code (J0570) became effective January 1, 2017 and coincides with the activation of a new field force to drive the next phase of Probuphine adoption (see also Braeburn Pharmaceuticals, Inc.).

"With patients and providers urgently needing access to evidence-based treatment for opioid addiction, we are pleased that CMS granted a J-code for Probuphine," said Behshad Sheldon, President and CEO, Braeburn Pharmaceuticals. "We anticipate that the new code and our expanded commercial team will advance adoption of Probuphine and broaden access for appropriate patients with opioid use disorder."

HCPCS codes are used by healthcare professionals to identify services and procedures for which they bill public or private health insurance programs. The codes included in the HCPCS set, which is based on the American Medical Association's Current Procedural Terminology, are maintained by CMS and universally accepted by all payers.

Keywords for this news article include: Braeburn Pharmaceuticals Inc., Medicaid, Medicare, Health Policy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC